Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VEE DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Venezuelan Equine Encephalitis (VEE) vaccine is delivered with PharmaJet precision delivery, needle-free injection system resulted in humoral and cellular immune responses significant protection against disease and viremia.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
November 16, 2023
Lead Product(s) : VEE DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SCIB1,Nivolumab,Ipilimumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Scancell
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ImmunoBody® vaccines are designed to induce potent cytotoxic CD8 T cell responses against multiple epitopes via a dual mechanism of action. These DNA vaccines are being used both for the treatment of cancer.
Brand Name : SCIB1
Molecule Type : Vaccine
Upfront Cash : Not Applicable
September 28, 2023
Lead Product(s) : SCIB1,Nivolumab,Ipilimumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Scancell
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Venezuelan Equine Encephalitis Virus DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : DTRA
Deal Size : $4.0 million
Deal Type : Agreement
Details : The funding will be used to further advance the clinical assessment of its Venezuelan Equine Encephalitis Virus (VEEV) DNA candidate vaccine in combination with either Tropis Intradermal (ID) or Stratis Intramuscular (IM) Systems.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
April 18, 2023
Lead Product(s) : Venezuelan Equine Encephalitis Virus DNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : DTRA
Deal Size : $4.0 million
Deal Type : Agreement
Lead Product(s) : SCOV1,SCOV2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Scancell
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Covidity (SCOV1 and SCOV2 vaccine), administered via needle-free intradermal injection, is a prophylactic DNA vaccine produces a durable immunity against the SARS-CoV-2 virus.
Brand Name : COVIDITY
Molecule Type : Vaccine
Upfront Cash : Not Applicable
March 21, 2023
Lead Product(s) : SCOV1,SCOV2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Scancell
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : HPV Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : $0.8 million
Deal Type : Funding
Details : Phase II grant from the National Institutes of Health (NIH), to evaluate the immunogenicity of intradermal administration of human papillomavirus virus (HPV) vaccine using their Tropis intradermal (ID) Needle-free Injection System (NFIS).
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
November 29, 2022
Lead Product(s) : HPV Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : $0.8 million
Deal Type : Funding
Lead Product(s) : Fractional Inactivated Poliovirus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : USAID
Deal Size : $1.5 million
Deal Type : Funding
Details : The project will measure vaccine coverage and cost using Tropis ID for fractional inactivated poliovirus vaccine (IPV) delivery compared to standard intramuscular delivery using needle and syringe (N/S).
Brand Name : fIPV
Molecule Type : Vaccine
Upfront Cash : Undisclosed
October 24, 2022
Lead Product(s) : Fractional Inactivated Poliovirus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : USAID
Deal Size : $1.5 million
Deal Type : Funding
Lead Product(s) : DNA-based Venezuelan Equine Encephalitis Virus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Military Health System Research Symposium
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Delivery of Venezuelan equine encephalitis DNA vaccine with PharmaJet Stratis® (Intramuscular – IM) or PharmaJet Tropis® (Intradermal – ID) Needle-free Injection System resulted in humoral and cellular immune responses significant protection agains...
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
September 12, 2022
Lead Product(s) : DNA-based Venezuelan Equine Encephalitis Virus Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Military Health System Research Symposium
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : DNA-based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The DNA-Based COVID-19 vaccine is one of few vaccines worldwide targeting the Omicron variant, rather than the original strain of the virus.As DNA vaccines can be modified easily the vaccine can be quickly adapted to future variants.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
August 16, 2022
Lead Product(s) : DNA-based COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : CV7201 mRNA
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : CureVac
Deal Size : Not Applicable
Deal Type : Not Applicable
PharmaJet Presents Latest Research Showing Benefits of Needle-free at mRNA-Based Therapeutics Summit
Details : CV7201 mRNA, is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein, can induce boostable functional antibodies against a viral antigen when administered with a needle-free device, although not when injected by a needle-syringe.
Brand Name : CV7201 mRNA
Molecule Type : Vaccine
Upfront Cash : Not Applicable
July 19, 2022
Lead Product(s) : CV7201 mRNA
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : CureVac
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ZyCoV-D
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Zydus Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Phase 3 interim clinical trial data of their plasmid DNA vaccine ZyCoV-D, highlights the overall effectiveness and protective efficacy against COVID-19 in expanded age groups when administered intradermally with the Tropis® intradermal System.
Brand Name : ZyCoV-D
Molecule Type : Vaccine
Upfront Cash : Not Applicable
April 27, 2022
Lead Product(s) : ZyCoV-D
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Zydus Pharmaceuticals
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?